Dr Laurence Legeai-Mallet, PhD
Imagine Institute, INSERM U1163, Université Paris Cité, Paris, France.
Dr Laurence Legeai-Mallet is senior Research Director at INSERM in the “Genetics of developmental disorders” laboratory at the Imagine Institute-Paris-France. She has been involved in the genetics of skeletal disease since 1993. Her research field ranges from the identification of disease genes involved in rare skeletal disorders, to the understanding of bone development.
She has a long-standing interest in FGFRs-related osteochondrodysplasias and her work, which combines experimental models and omics approaches, has contributed to our understanding of the role of cartilage, bone formation, and bone repair in skeletal development. Her team is also internationally recognized for proof-of-concept studies and breakthrough preclinical studies in achondroplasia, hypochondroplasia and Crouzon syndrome.
In 2009, she has developed the first therapeutic approaches for osteochondrodysplasia. In 2012, she reported with BioMarin the therapeutic potential of Vosoritide as the first investigational therapy for the most frequent cause of dwarfism, achondroplasia. In 2016, she demonstrated the positive effect of infigratinib low dose on bone growth in a mouse model of achondroplasia. In 2025, Laurence Legeai-Mallet and Tyra Biosciences reported positive results from preclinical assessing the investigational oral FGFR3-selective inhibitor Tyra300 in two Fgfr3 mouse models. In parallel, QED Therapeutics and Laurence Legeai-Mallet team using preclinical mouse models, have observed that infigratinib improved skeletal growth metrics, supporting its further development as a targeted treatment for hypochondroplasia.
Dr Legeai-Mallet current research programs focus on developing new therapeutic approaches for chondrodysplasias and craniosynostoses, and on the understanding the basic cellular and molecular mechanisms underlying skeletal development anomalies in rare skeletal disorders.